Fluicell AB (FLUI) - Total Assets
Based on the latest financial reports, Fluicell AB (FLUI) holds total assets worth Skr16.38 Million SEK (≈ $1.76 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check FLUI capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Fluicell AB - Total Assets Trend (2014–2024)
This chart illustrates how Fluicell AB's total assets have evolved over time, based on quarterly financial data. Check Fluicell AB tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Fluicell AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Fluicell AB's total assets of Skr16.38 Million consist of 81.3% current assets and 18.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr15.92 Million | 62.4% |
| Accounts Receivable | Skr1.38 Million | 5.4% |
| Inventory | Skr3.35 Million | 13.1% |
| Property, Plant & Equipment | Skr1.14 Million | 4.5% |
| Intangible Assets | Skr3.64 Million | 14.3% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Fluicell AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Fluicell AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fluicell AB's current assets represent 81.3% of total assets in 2024, a decrease from 94.5% in 2014.
- Cash Position: Cash and equivalents constituted 62.4% of total assets in 2024, down from 67.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is cash and equivalents at 62.4% of total assets.
Fluicell AB Competitors by Total Assets
Key competitors of Fluicell AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Fluicell AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 4.48 | 4.29 |
| Quick Ratio | 0.61 | 3.94 | 3.93 |
| Cash Ratio | 0.18 | 3.16 | 0.00 |
| Working Capital | Skr1.09 Million | Skr19.35 Million | Skr17.55 Million |
Fluicell AB - Advanced Valuation Insights
This section examines the relationship between Fluicell AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | 173.1% |
| Total Assets | Skr25.51 Million |
| Market Capitalization | $5.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fluicell AB's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Fluicell AB's assets grew by 173.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fluicell AB (2014–2024)
The table below shows the annual total assets of Fluicell AB from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr25.51 Million ≈ $2.75 Million |
+173.10% |
| 2023-12-31 | Skr9.34 Million ≈ $1.01 Million |
-70.60% |
| 2022-12-31 | Skr31.77 Million ≈ $3.42 Million |
+17.73% |
| 2021-12-31 | Skr26.98 Million ≈ $2.90 Million |
+8.66% |
| 2020-12-31 | Skr24.83 Million ≈ $2.67 Million |
+24.54% |
| 2019-12-31 | Skr19.94 Million ≈ $2.15 Million |
-23.24% |
| 2018-12-31 | Skr25.97 Million ≈ $2.80 Million |
+125.17% |
| 2017-12-31 | Skr11.54 Million ≈ $1.24 Million |
+315.68% |
| 2016-12-31 | Skr2.77 Million ≈ $298.63K |
+62.66% |
| 2015-12-31 | Skr1.71 Million ≈ $183.59K |
+2.04% |
| 2014-12-31 | Skr1.67 Million ≈ $179.92K |
-- |
About Fluicell AB
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of mu… Read more